Trade 4D Molecular Therapeutics Inc - FDMT CFD

4D Molecular Therapeutics, Inc. Company profile

About 4D Molecular Therapeutics Inc

4D Molecular Therapeutics, Inc. is a clinical-stage stage gene therapy company. The Company is focused on developing targeted therapies based on its adeno-associated viruses (AAV) vectors. It uses its Therapeutic Vector Evolution platform to customize its AAV vectors to target specific tissue types associated with the disease. The Company is focuses on three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector), and pulmonology (aerosol vector). The Company's product candidates include 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), 4D-110 for the treatment of choroideremia, 4D-310 for the treatment of Fabry disease, 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and 4D-710 for the treatment of cystic fibrosis lung disease.

Financial summary

BRIEF: For the nine months ended 30 September 2021, 4D Molecular Therapeutics Inc revenues increased 23% to $17.9M. Net loss increased 28% to $46.2M. Revenues reflect Switzerland segment increase of 21% to $17.2M, Netherlands segment increase of 43% to $723K. Higher net loss reflects General and administrative - Balancing increase of 72% to $15.5M (expense), Stock-based Compensation in SGA increase from $1.4M to $5.2M (expense).